Halozyme Therapeutics, Inc. provided earnings guidance for the twelve months ended December 31, 2023. The company estimates 2023 revenue will be in the range of $827 million to $832 million, net income will be in the range of $292 million to $297 million and GAAP Diluted EPS will be in the range of $2.18 to $2.21.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
54.75 USD | -0.64% |
|
+3.38% | +48.13% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+48.13% | 7.01B | |
+20.03% | 126B | |
+23.61% | 118B | |
+23.26% | 27.87B | |
-18.07% | 20.95B | |
-15.13% | 16.92B | |
-14.81% | 16.18B | |
+9.78% | 14.84B | |
-46.10% | 14.79B | |
+52.34% | 14.08B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Twelve Months Ended December 31, 2023